This process was accompanied by the release of abundant inflammatory factors, such as interleukin-1β (IL-1β) and interleukin-18 (IL-18), which significantly enhanced the recruitment and activation of tumor-infiltrating lymphocytes (TILs) and CD8+ T cells. The gene discussed is IL18; the disease is neoplasm.